An act to add Section 1374.
The introduction of SB 535 is expected to significantly impact state health care laws by mandating insurance coverage for a wider range of obesity-related treatments. Currently, the coverage is often limited to individuals who qualify as having 'morbid obesity.' This bill seeks to eliminate the stigma associated with obesity by providing comprehensive treatment options before patients reach a more severe level of the condition. The legislation aligns with the findings of major medical organizations that recognize obesity as a serious chronic disease associated with various comorbidities and increased risk of mortality.
Senate Bill No. 535, also known as the Obesity Treatment Parity Care Access Act, aims to enhance health care coverage for the treatment of obesity. If enacted, this bill requires health care service plans and health insurance policies that provide outpatient prescription drug benefits to cover intensive behavioral therapy, bariatric surgery, and at least one FDA-approved antiobesity medication for individuals diagnosed with obesity. The bill is designed to ensure that these services are available starting January 1, 2026, thereby addressing a critical gap in obesity treatment coverage under current California law.
The sentiment surrounding SB 535 appears to be largely supportive among health advocates and organizations that champion health equity. Proponents argue that the bill is a necessary step toward combating the rising obesity epidemic and addressing its associated health disparities, especially among marginalized communities. While the bill has garnered legislative support, there may be concerns from some sectors of the healthcare insurance industry regarding the potential increase in costs associated with comprehensive coverage for obesity treatments.
Notably, one point of contention surrounding SB 535 is related to concerns about the financial implications for health insurers, who may oppose mandates that they perceive as increasing their costs. Furthermore, there may be debates over the appropriateness of mandating coverage for treatments that some stakeholders might argue are lifestyle-related versus medically necessary interventions. These discussions underline the ongoing conflict between ensuring comprehensive health care access and managing healthcare costs.